Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, Maria de Miguel, S.J. Harris, Irene Moreno Candilejo, Priya Sriskandarajah, Wen Xu, Mariana Scaranti, Anastasia Constantinidou, Jenny King, Mona Parmar, Alison Turner, Suzanne Carreira, Ruth Riisnaes, Laura Finneran, Emma Hall, Yuji Ishikawa, Kiyohiko Nakai, Nina Tunariu, Bristi Basu, Martin Kaiser, Juanita Lopez, Anna Minchom, Johann S. de Bono, Udai Banerji
Topics & Concepts
MedicineDosingRefractory (planetary science)Multiple myelomaToxicityResponse Evaluation Criteria in Solid TumorsInternal medicineOncologyGastroenterologyPhases of clinical researchPharmacologyAstrobiologyPhysicsMelanoma and MAPK PathwaysMultiple Myeloma Research and TreatmentsBioactive Compounds in Plants